SLC5A2 and kidney disorder: Fourth, emerging treatments such as glucagon-like peptide 1 receptor agonists have shown promise in reducing kidney disease progression risk [20], and future studies should assess their added benefit in individuals already being treated with SGLT2 inhibitors.